Pregabalin Capsule
Product Images NDC 60760-681

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-681). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

681-30 (Pregabalin 60760 681 30)

Label for Pregabalin Capsules 100 mg by St. Mary's Medical Park Pharmacy. The label displays the product name, strength, dosage form, and quantity of 30 capsules. It includes manufacturing details by Alkem Laboratories Ltd., Mumbai, India, and mentions storage instructions for controlled room temperature (15°-30°C). The label features multiple identical product identification sections with coded lot and expiry placeholders.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A formula calculating Creatinine Clearance (CLCr) shown as [(140 - age in years) × weight in kg] divided by [72 × serum creatinine in mg/dL], with a multiplier of 0.85 for female patients. The equation is presented clearly in black text on a white background.*

FDA Label Image

Pregabalin-fig-a (Pregabalin Fig A)

Bar chart showing the responder rate percentages for three groups: Placebo (22.6%, N=93), 2.5 mg/kg/day dose (29.1%, N=103), and 10 mg/kg/day dose (40.6%, N=96). The x-axis lists treatment groups with sample sizes, and the y-axis shows responder rate percentages from 0 to 60%.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar graph comparing responder rates (%) in two clinical studies, Study E1 and Study E3, for Pregabalin dosed at various amounts. The x-axis shows dosing groups including placebo and Pregabalin doses with frequency (BID, TID), while the y-axis shows responder rates from 0% to 60%. Study E1 includes placebo, 50, 150, 300, and 600 mg/day (all BID), with rates rising to 51%. Study E3 compares placebo, 600 mg/day BID, and 600 mg/day TID doses, with highest response at 49%. A note indicates statistical significance versus placebo.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph showing seizure reduction as median percent change from baseline on the vertical axis versus dose in mg/day on the horizontal axis. It compares multiple studies (Study E1 BID, Study E2 TID, Study E3 BID, Study E3 TID) with dose groups including placebo (0 mg), approximately 50 mg, 150 mg, 300 mg, and higher doses. Data points show increasing seizure reduction with higher doses, and p-values indicating significance are noted for each comparison.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph displaying the percent of patients improved versus percent improvement in pain from baseline. Four lines represent different groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The vertical axis shows patient improvement percentages, and the horizontal axis shows percent pain improvement increments from baseline.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph illustrating the percent of subjects improved over time, comparing Pregabalin and placebo groups. The x-axis represents percent improvement from baseline to week 12 BOCF, ranging from 0 to 100, and the y-axis shows percent of subjects improved, also ranging from 0 to 100. Pregabalin shows a consistently higher improvement percentage than placebo.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph depicting the percentage of subjects improved from baseline to Week 16 BOCF for Pregabalin versus placebo. The x-axis represents percent improvement, while the y-axis shows the percent of subjects improved, comparing treatment effects over time.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg taken three times a day with placebo across various levels of pain improvement.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph illustrating percent improvement in pain from baseline over time in days for patients taking Pregabalin at 75 mg, 150 mg, and 300 mg twice daily, compared to placebo. The graph shows decreasing pain improvement percentages across the 0 to 100-day period for each dosage group and placebo.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line chart comparing the percent of patients improved versus percent improvement in pain from baseline. It includes three lines representing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing patient response to different dosages and placebo over a range of pain improvement percentages.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph showing the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo. The graph illustrates patient improvement trends for these three treatments over a range of pain improvement percentages.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg, as well as a placebo group. The lines indicate higher patient improvement percentages with increasing Pregabalin doses compared to placebo.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A survival curve chart showing estimated percentage of subjects without LTR over 180 days. Two lines compare Pregabalin versus Placebo, with the Pregabalin line consistently above the Placebo line, indicating higher percentages of subjects without LTR throughout the timeframe.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure diagram of pregabalin, illustrating its molecular framework with functional groups including an amino group (NH2) and a carboxylic acid group (CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.